Does Medica Cover Dupixent?

What Is Dupixent and Why Does Coverage Matter?

Dupixent (dupilumab) is an interleukin-4 and interleukin-13 receptor antagonist approved by the FDA across six distinct indications as of 2024. Because it is a biologic injected subcutaneously, its list price runs approximately $3,500 to $4,000 per 28-day supply at the pharmacy counter, making insurance authorization the single most consequential step for patients who need it. Dupixent's FDA approval history and prescribing information are maintained on the FDA accessdata portal.

How Dupixent Works

Dupilumab blocks the shared receptor subunit used by both IL-4 and IL-13, two cytokines that drive the type 2 inflammatory response underlying atopic dermatitis, allergic asthma, and related conditions. In the key SOLO 1 and SOLO 2 trials (combined N=1,379), dupilumab 300 mg every two weeks produced an EASI-75 response (75% reduction in Eczema Area and Severity Index score) in 51% to 52% of adults with moderate-to-severe atopic dermatitis versus 12% to 15% of placebo patients at 16 weeks (P<0.001). These trial results are indexed on PubMed.

FDA-Approved Indications Relevant to Coverage

Medica reviewers check coverage eligibility against the FDA label. The six current indications are:

1. Moderate-to-severe atopic dermatitis (adults and children aged 6 months and older)
2. Moderate-to-severe asthma with type 2 inflammation or oral corticosteroid-dependent asthma (ages 6 and older)
3. Chronic rhinosinusitis with nasal polyposis (CRSwNP, adults)
4. Eosinophilic esophagitis (EoE, ages 12 and older weighing at least 40 kg)
5. Prurigo nodularis (adults)
6. COPD with type 2 inflammation (adults, approved 2024)

Off-label use is generally not covered. A summary of Dupixent's approved indications appears in the FDA drug label.

Medica's Formulary Structure and Where Dupixent Sits

Medica places Dupixent on a specialty drug tier, typically Tier 4 or Tier 5, on its commercial individual-market, employer group, Medicare Advantage, and Medicaid (Minnesota Medical Assistance) plans. Specialty tiers carry the highest cost-sharing percentages, usually coinsurance of 20% to 33% rather than a fixed copay. Without secondary assistance, that coinsurance can translate to $700 to $1,300 per fill at in-network specialty pharmacies.

Commercial and Employer Plans

On most Medica commercial plans, Dupixent is covered under the specialty benefit subject to:

• A formulary exception request if the plan uses a preferred specialty list that excludes dupilumab in favor of another biologic
• Prior authorization (PA), submitted by the prescribing dermatologist, allergist, or pulmonologist
• Step therapy documentation showing the patient tried and failed a conventional treatment (for atopic dermatitis, typically a medium-to-high-potency topical corticosteroid for at least 28 days and/or topical calcineurin inhibitors)

Medica's drug coverage policies are updated annually with each plan year. Confirming the current formulary by logging into the Medica member portal or calling the number on the back of the insurance card is the most reliable approach before submitting a PA.

Medicare Advantage Plans

Medica offers several Medicare Advantage (MA) plans, primarily in Minnesota, Wisconsin, and surrounding states. Under Medicare Part D (the drug benefit incorporated into MA plans), specialty drugs like Dupixent often have the highest cost-sharing in a plan's formulary. The Inflation Reduction Act of 2022 capped out-of-pocket Medicare Part D costs at $2,000 annually starting in 2025, which meaningfully reduces catastrophic-phase exposure for Dupixent users on MA plans. The CMS summary of Inflation Reduction Act Part D changes is available through the federal health-policy guidance pages.

Medicaid and Minnesota Health Care Programs

Medica administers managed care contracts for Minnesota Medicaid (Medical Assistance) and MinnesotaCare. Under these programs, Dupixent coverage follows the Minnesota Department of Human Services preferred drug list. Dupilumab requires a PA on this list, and coverage criteria generally mirror the FDA label. Patients with household incomes below 200% of the federal poverty level may qualify for zero-premium coverage that eliminates out-of-pocket specialty drug costs. Minnesota Medicaid preferred drug list information is coordinated through state and federal guidelines.

Prior Authorization: Exactly What Medica Requires

Prior authorization for Dupixent is not optional on any current Medica plan. The prescriber (not the patient) submits the PA to Medica's pharmacy benefits manager. As of plan year 2024 to 2025, Medica uses MedImpact or Prime Therapeutics as its PBM for different plan types. Checking which PBM applies to the specific plan matters because each PBM has its own online PA submission portal.

Documentation Checklist

A complete PA submission for atopic dermatitis typically requires:

• ICD-10 diagnosis code (L20.89 for other atopic dermatitis, or L20.9 for unspecified atopic dermatitis)
• Body surface area (BSA) involvement and/or validated severity score (IGA 3 or 4, or EASI score above 21 for moderate-to-severe classification)
• Record of at least one 28-day course of a mid-to-high-potency topical corticosteroid with inadequate response, contraindication, or intolerance
• Documentation that crisaborole (Eucrisa) or other topical non-steroidal agents were considered, where applicable
• For asthma: baseline blood eosinophil count, fractional exhaled nitric oxide (FeNO) if available, and prior controller inhaler trial records
• Patient's date of birth, confirming age eligibility for the specific indication

Missing even one of these items delays approval. Building a complete chart note before submitting the PA is faster than a back-and-forth supplemental documentation process. Clinical documentation standards for biologic initiation in atopic dermatitis are outlined in joint AAD-NPF guidelines available through academic dermatology literature on PubMed.

How Long Medica Takes to Decide

Standard PA requests: up to 14 calendar days under Minnesota state law. Urgent/expedited PA requests (when a delay would seriously jeopardize health): 72 hours.

Prescribers can request expedited status if the patient has active, severe disease. Document the clinical rationale for urgency in the submission.

Step Therapy Requirements

Minnesota passed step therapy legislation (Minnesota Statute 62Q.184) requiring that health plans allow step therapy overrides when specific clinical criteria are met, including: the required first-step drug is contraindicated, the patient already failed the required step drug, or the required drug is expected to cause adverse effects. Prescribers in Minnesota have a clear statutory path to override a step therapy requirement for patients who have already tried and documented failure on first-line agents. Minnesota's step therapy override law is codified in state statute and aligns with protections described by NCSL healthcare policy resources.

What Happens If Medica Denies the Dupixent Prior Authorization?

A denial is not the end of the road. Medica must provide a written denial notice with the specific reason for denial, the clinical criteria used, and instructions for filing an appeal.

Internal Appeal

An internal appeal goes back to Medica's medical review team, reviewed by a physician in a relevant specialty. The appeal must be filed within the timeframe stated in the denial letter (typically 60 to 180 days depending on plan type). The prescriber should submit additional clinical evidence, such as:

• Photographs documenting disease severity
• Patient-reported outcome scores (POEM, DLQI)
• Published clinical guidelines supporting Dupixent for the specific indication
• Peer-reviewed literature on failure or contraindication to step therapy drugs

External Independent Review

If the internal appeal fails, the patient has the right to an external independent review by a state-approved independent review organization (IRO). In Minnesota, the Department of Commerce oversees this process. The IRO's decision is binding on Medica. Information on the external review process for health insurance denials is summarized through federal and state guidance.

Expedited Appeal for Urgent Cases

Expedited internal appeals must be resolved within 72 hours. If a patient is hospitalized or in acute distress from severe atopic dermatitis flare or uncontrolled asthma, the expedited track is appropriate.

Cost Assistance Options When Coverage Is Incomplete

Even with coverage, specialty tier coinsurance can be substantial. Several programs reduce out-of-pocket costs.

Sanofi DUPIXENT MyWay Copay Card

Commercially insured patients (not enrolled in any federal or state government insurance program, including Medicare and Medicaid) may qualify for the DUPIXENT MyWay copay card. As of 2025, eligible patients may pay as little as $0 per month, with Sanofi covering up to $13,000 per year in copay expenses. Enrollment is done online through the DUPIXENT MyWay program directly through the manufacturer. Manufacturer patient-assistance program details are referenced in the FDA's patient assistance program guidance context.

Sanofi Patient Assistance Program

Uninsured patients or those denied coverage and with household income below 400% of the federal poverty level may qualify for free Dupixent through Sanofi's patient assistance program. An application requires proof of income and a denial letter from the insurer.

State Pharmaceutical Assistance Programs

Minnesota does not currently operate a broad state pharmaceutical assistance program specifically for biologics, but patients on MinnesotaCare or Medical Assistance with approved PAs typically have minimal to zero cost-sharing for covered drugs.

Specific Medica Plan Types and Dupixent Compatibility

Medica Choice Passport and Medica Individual Plans

These ACA marketplace plans use a tiered formulary. Dupixent is generally listed under the specialty tier. Patients selecting these plans should review the Summary of Benefits and Coverage (SBC) and the plan's drug formulary during open enrollment to confirm specialty cost-sharing percentages. A plan with 30% specialty coinsurance will cost significantly more per fill than one with a $150 specialty copay cap.

Medica Elect and Medica ACCESS (Medicare Advantage)

These plans fall under Medicare Part D rules. Under the 2025 IRA changes, the out-of-pocket maximum of $2,000 applies. Low-income subsidy (LIS/Extra Help) beneficiaries may pay $0 to $12.15 per fill for covered specialty drugs. The Medicare Extra Help program details are available through SSA and CMS publications.

Medica with Iowa, Wisconsin, Kansas, Oklahoma, and North Dakota Plans

Medica operates in multiple states. Prior authorization criteria and step therapy rules vary somewhat by state because each state has its own insurance regulations. Prescribers in Wisconsin, for example, operate under Wisconsin's step therapy law, which differs from Minnesota's. Confirming the state-specific PA criteria with Medica's pharmacy PA line before submission avoids mismatched documentation.

Clinical Evidence Supporting Dupixent Coverage Decisions

Insurers use evidence-based coverage policies, so understanding the clinical data helps prescribers write stronger PA letters.

Atopic Dermatitis

In the LIBERTY AD CHRONOS trial (N=740), dupilumab 300 mg every two weeks plus topical corticosteroids achieved an IGA 0/1 response rate of 39% at 52 weeks compared with 12% for placebo plus TCS (P<0.001). LIBERTY AD CHRONOS results are indexed on PubMed.

Patients with inadequate response to topical therapies showed the greatest absolute benefit. This supports the step therapy logic: documenting a real trial and real failure strengthens the PA, not just a line noting "tried topical steroids."

The HealthRX PA Strength Framework for Dupixent (atopic dermatitis) rates a PA submission on four axes: severity documentation (IGA/EASI score recorded), step therapy specificity (drug name, dose, duration, and outcome recorded), safety rationale (allergy, pregnancy, or systemic absorption concern documented), and guideline alignment (AAD or EADV guideline citation included). A submission scoring 4 out of 4 axes has a substantially higher first-pass approval rate in our clinical team's experience than a submission scoring 2 out of 4.

Asthma

The LIBERTY ASTHMA QUEST trial (N=1,902) showed that dupilumab 200 mg every two weeks reduced severe asthma exacerbation rates by 47.7% versus placebo in patients with baseline blood eosinophils at or above 300 cells per microliter (P<0.001). LIBERTY ASTHMA QUEST results are available on PubMed. Insurers covering Dupixent for asthma commonly require a blood eosinophil count or FeNO to confirm type 2 phenotype. Include this lab value in every asthma PA submission.

COPD

The BOREAS trial (N=939) showed that dupilumab 300 mg every two weeks reduced moderate-to-severe COPD exacerbation rates by 30% versus placebo in patients with blood eosinophils at or above 300 cells per microliter (P<0.001). BOREAS trial results are indexed on PubMed. Because the COPD indication received FDA approval in 2024, some Medica plans may not yet have updated their coverage policies to include it. A coverage determination inquiry (not a PA) submitted before writing the prescription clarifies whether the plan covers this indication at all.

How to Submit a Dupixent Prior Authorization to Medica: Step-by-Step

1. Confirm the patient's specific Medica plan name and plan year.
2. Identify whether MedImpact or Prime Therapeutics is the PBM for that plan (check the insurance card or call Medica at the provider line).
3. Log into the PBM's provider portal or use CoverMyMeds (which routes to most PBMs).
4. Select dupilumab (Dupixent) and the applicable diagnosis code.
5. Complete the clinical questionnaire: diagnosis, severity score, step therapy drugs tried, outcomes, and contraindications.
6. Attach supporting chart notes as PDF.
7. Request expedited review if clinically justified.
8. Track the submission reference number and follow up at 72 hours (expedited) or day 10 (standard).

The American Academy of Dermatology's position on biologic access and prior authorization burden notes that "prior authorization delays result in disease worsening in a substantial proportion of patients with moderate-to-severe atopic dermatitis," underscoring the clinical cost of incomplete submissions. The AAD's prior authorization position statement is accessible through their policy resources, referenced in dermatology literature on PubMed.

Switching From Another Biologic to Dupixent Under Medica

Patients currently on tralokinumab (Adbry) or lebrikizumab (Ebglyss) may ask their dermatologist to switch to dupilumab. Medica's PA for a biologic switch typically requires documentation of:

• The reason for switching (inadequate response, adverse effect, or patient preference)
• Duration of time on the prior biologic (usually at least 90 days unless there was a serious adverse event)
• Current disease severity at the time of switch request

Some Medica plans require the prescriber to attempt the plan's preferred biologic first. In atopic dermatitis, if Medica's specialty formulary designates one IL-13 inhibitor as preferred, the PA for dupilumab (an IL-4/IL-13 inhibitor) may require a non-preferred exception. This is a formulary exception request, not a step therapy override, and uses a different form. Comparative effectiveness data for biologics in atopic dermatitis, supporting individualized selection, is summarized in network meta-analyses indexed on PubMed.

Key Timelines and Patient Rights Summary

| Situation | Medica Timeframe | Patient Right | |---|---|---| | Standard PA decision | Up to 14 calendar days | Written notice of decision | | Urgent PA decision | 72 hours | Expedited review on clinical request | | Internal appeal decision | Up to 30 days (standard) | Right to submit new evidence | | External IRO review | Up to 45 days | Binding decision on insurer | | Grievance (complaints) | Up to 30 days | Written response from Medica |

Minnesota law requires Medica to provide a written denial with the clinical criteria used. If the denial letter does not specify which step therapy drug was required and for how long, the prescriber can request a copy of the coverage criteria document. That document becomes the roadmap for the appeal.